Objective: To characterise the demographic and clinical characteristics of cervical dystonia (CD) patients presenting for routine treatment with botulinum neurotoxin-A (BoNT-A) across different regions.

Background: BoNT-A injection is first-line treatment for CD. However, there is likely considerable heterogeneity in international clinical practice.

Methods: An analysis of verified Baseline/first injection visit data from CD subjects enrolled in the ongoing INTEREST IN CD2 observational study. This study includes subjects from 34 countries grouped into the following regions: Asia, Australia, Europe, Latin America, North Africa/Middle East and USA.

Results: Table 1 details the baseline demographic and clinical data for the overall population and per region. Data related to previous treatment with BoNT-A are given in Table 2. Subjects in USA and Australia tended to be older than subjects in other regions (but average time since diagnosis was similar). The majority of subjects in USA and Australia (81% & 64%, respectively) were re-treated with BoNT within 12-16 weeks, the majority of subjects in Latin America and Asia (81% and 72%, respectively) had an injection interval of >16 weeks.

Conclusions: There are likely important differences in the baseline demographics, clinical characteristics, and BoNT-A injection practices for CD patients presenting for routine treatment. Such differences may be a result of access to treatment, or other socio-economic factors. The ongoing INTEREST IN CD2 will collect data on how these differences may impact on patient satisfaction with BoNT-A treatment.

« Back to 2016 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/international-differences-in-the-baseline-characteristics-and-clinical-management-of-cervical-dystonia-patients-presenting-for-botulinum-toxin-treatment-in-routine-practice/